Actively Recruiting
Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention: A Randomized Control Trial
Led by National Institute of Cardiovascular Diseases, Pakistan · Updated on 2026-04-22
1148
Participants Needed
2
Research Sites
30 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effect of adenosine pre-medication on the occurrence of slow flow or no-reflow after primary percutaneous coronary intervention (PCI) in adults with ST-segment elevation myocardial infarction (STEMI). This study is a randomized controlled trial involving 1,148 patients, designed to assess whether giving adenosine before PCI can improve heart muscle blood flow and reduce complications associated with inadequate myocardial perfusion. Participants will be randomly assigned to one of two groups: one group will receive intracoronary adenosine before PCI along with standard pharmacological treatment, while the control group will receive only standard care during PCI. The adenosine dose is 2 mg for the left coronary artery and 1 mg for the right coronary artery, diluted in 20 mL normal saline, administered immediately before the procedure. The study will take place over 12 months at multiple centers. During the study, researchers will collect baseline and procedural data, monitoring the incidence of slow flow or no-reflow using TIMI flow grades during the PCI procedure. They will also assess myocardial perfusion through the Myocardial Blush Grade. Safety will be monitored for potential side effects such as transient bradycardia or heart block. Statistical analysis will evaluate the outcomes, and participants will be followed until the study concludes at the end of 2026.
CONDITIONS
Brief Title
Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients of either sex aged 18 years or older
- Diagnosis of acute ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI
You will not qualify if you...
- Presence of cardiogenic shock at presentation
- Presence of heart block
- Allergy to adenosine
- Refusal to give consent for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single procedure day
Participants receive intracoronary adenosine pre-medication immediately prior to primary percutaneous coronary intervention (PCI) or standard pharmacological management alone during the PCI procedure.
1 visit (in-person)
Trial Site Locations
Total: 2 locations
1
National Institute of Cardiovascular Diseases
Karachi, Sindh, Pakistan, 75510
Actively Recruiting
2
National Institute of Cardiovascular Diseases
Karachi, Sindh, Pakistan, 75510
Actively Recruiting
Research Team
M
Muhammad Nauman Khan, FCPS
K
Khalid Naseeb, FCPS
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here